Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX 2 75 10 SULFITE FREE IN DEXTROSE 10 IN PLASTIC CONTAINER versus NOVAMINE 11 4.
Head-to-head clinical analysis: CLINIMIX 2 75 10 SULFITE FREE IN DEXTROSE 10 IN PLASTIC CONTAINER versus NOVAMINE 11 4.
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER vs NOVAMINE 11.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Parenteral nutrition providing amino acids for protein synthesis and dextrose for caloric support, bypassing gastrointestinal tract.
Amino acid solution providing essential and non-essential amino acids for protein synthesis and nitrogen balance in parenteral nutrition.
Intravenous administration of 2.75% amino acids and 10% dextrose at a rate to provide 1-2 g protein/kg/day and 5-25 g dextrose/kg/day based on metabolic needs. Infusion rate not to exceed 0.5 g dextrose/kg/hour initially.
Intravenous infusion: initial dose 1.5 mL/kg/day (0.17 g amino acids/kg/day) increased by 0.5 mL/kg/day to 2.0-3.0 mL/kg/day (0.23-0.34 g amino acids/kg/day) maximum 3.5 mL/kg/day (0.4 g amino acids/kg/day). Infusion rate not to exceed 0.1 mL/kg/hour in neonates and 0.2 mL/kg/hour in older patients.
None Documented
None Documented
Not applicable; components are endogenously regulated (amino acids: minutes to hours; dextrose: ~1-2 hours). For continuous infusion, steady-state achieved within 4-6 hours.
Variable, dependent on amino acid profile; net protein synthesis occurs over 4-6 hours post-infusion; no classical terminal half-life; clinical steady state achieved within 24-48 hours of continuous infusion.
Renal: ~50% as unchanged amino acids and dextrose metabolites within 6 hours; remainder metabolized to CO2 and H2O, eliminated via lungs and urine.
Amino acids are metabolized via transamination and deamination; nitrogen is excreted renally as urea (75-90%), with minimal biliary/fecal elimination (<5%).
Category C
Category C
Parenteral Nutrition
Parenteral Nutrition